Introduction
============

In 2004, Malawi initiated a public health approach to HIV care and treatment services. The programme aimed to deliver antiretroviral therapy (ART) to all eligible HIV-positive individuals presenting to decentralized clinics, with minimal reliance on laboratory support for determining eligibility and for monitoring patients in care.[@dyw208-B1]^,^[@dyw208-B2] Early success of this initiative was evident within the first year of scale-up, with increased survival among those started on treatment[@dyw208-B3] and declines in all-cause mortality rates at the population level.[@dyw208-B4]

Since the scale-up of ART programmes, substantial reductions in adult mortality [@dyw208-B5] and improved life expectancy among HIV-positive individuals on ART[@dyw208-B6] have been observed in other high HIV prevalence sub-Saharan African (SSA) countries. However, the trends in all-cause and cause-specific mortality patterns in HIV-positive individuals who are not (yet) receiving ART are not well described. Understanding the temporal trends in these different groups is essential for evaluating the impact of future test and treat strategies and establishing whether continued improvement in mortality might be expected in proportion to the increased burden of ART care.[@dyw208-B10]^,^[@dyw208-B11]

Although introduced nationally in 2004, ART was not available free at the point of care in northern rural Malawi until July 2005. Within a year, all-cause mortality had declined by 16%[@dyw208-B4] and within the next 2 years, mortality declined by 32%.[@dyw208-B12] In this population, deaths attributable to HIV in adults, as assigned by verbal autopsy, decreased from 42% in 2005 to 17% in 2009.[@dyw208-B13] It is not clear if these early improvements in mortality are sustained beyond this time, during a period of increasingly decentralized ART care, and where there is little availability of CD4 cell counts or viral load monitoring for those on long-term treatment.

This study uses population-level demographic and HIV test data from northern rural Malawi to investigate the effect of the ART programme on life expectancy and adult all-cause and cause-specific mortality, including HIV-positive individuals with and without ART uptake, covering a 9-year period of scale-up of ART availability through increasingly decentralized care.

Methods
=======

Setting
-------

The Karonga demographic surveillance site (DSS), was established in 2002 in a rural population of nearly 33 000 individuals in northern Malawi, and conducts continuous demographic surveillance, with rigorous identification procedures permitting linkage to data collected in other studies nested within the surveillance population.[@dyw208-B14]

HIV counselling and testing (HCT) of the DSS population has been conducted for various studies since 1985. In 2005--06, HIV prevalence was estimated at 11.5%[@dyw208-B15] from a population-representative stratified sample sero-survey in those aged 18 to 59 years. Four annual house-to-house cross-sectional HIV sero-surveys were conducted between September 2007 and September 2011, for all individuals aged 15 years or older, involving counselling, enquiry about previous HIV testing and ART uptake start date, and rapid HIV testing with results available to participants. By 2010, HIV prevalence had declined to 8%.[@dyw208-B16] In 2013, an additional survey invited participants aged 18 years and older who had missed earlier rounds to screen for HIV infection, using rapid testing with results immediately available.

ART became available in Karonga District Hospital, 70 km north of the DSS area, in July 2005. Within the DSS, ART was first available from a single rural hospital in 2006,[@dyw208-B12] then from an additional health centre in 2010 and then from three further health centres between 2011 and early 2012. In the wider Karonga district, there were four ART clinics in 2008, six clinics in 2010 and 16 clinics by the end of 2012.[@dyw208-B17] From 2005 to 2010, individuals were eligible for ART if they were in World Health Organization (WHO) clinical stage 3 or 4 or had a CD4 cell count \< 250 cells/mm. This was extended to CD4 \< 350 cells/mm[@dyw208-B3] in 2011 (and to \< 500 cells/mm[@dyw208-B3] in July 2014, after this study period). Throughout the period of this study, CD4 cell counts were not consistently available and viral load monitoring was not available in the surveillance area. Before and during ART roll-out there was a policy to provide preventative care to all HIV-positive patients, including nutritional support, TB screening and treatment and prophylactic cotrimoxazole antibiotics, although delivery was variable.

By mid-2008, ART uptake in the DSS area was estimated to be at least 60% of those eligible, with greater uptake (65%) in women than in men (48%).[@dyw208-B18] In the district, 6-month retention in care increased from 70% in the first 2 years of ART availability to 92% in 2011--12.[@dyw208-B17]

Data sources
------------

Information relating to an individual's first ART start date was collected through interviews and linked ART records. If conflicting data were observed between clinic register and self-reported ART start dates, the clinic-register date was used. Individual-level data on pre-ART care was not available for this analysis. HIV test results were obtained from testing conducted in population-level and clinic-based studies between 2005 and 2014. Socio-demographic data, including location of residence (\< 1 km, ≥ 1 km to tarmac road) and highest level of education (none/primary incomplete, primary complete, secondary incomplete, secondary complete/tertiary) were obtained from the annual census and continuous demographic surveillance.

Cause of death (HV-related, non-HIV-related) was ascertained from verbal autopsy data. The verbal autopsies are conducted following all deaths in the DSS, by medical assistants with additional training using a semi-structured questionnaire adapted from the standard World Health Organization questionnaire. Whenever possible, the informant is a close relative of the deceased and nursed them through their final illness, and the information is collected approximately 2--4 weeks after the death. Each verbal autopsy questionnaire is independently reviewed by two clinicians, and in the event of discrepancies a third reviewer assigns the cause of death after viewing the initial two reviews. Data on HIV status may be available to the reviewer within the verbal autopsy questionnaire or through access to the HIV test database, if the deceased had participated in a study providing HIV testing. If a decision cannot be made on the cause, the death is coded as un-specifiable. Of all adult deaths, 9% were either unspecified or unknown.

Statistical analysis
--------------------

The analysis was restricted to adults aged 15 years or older. To assess life expectancy trends, individuals contributed exposure time during their residence in the DSS from January 2003 (the start of demographic surveillance in the area, including a period preceding population-level HIV testing and ART availability), or their date of in-migration, if later, until the earliest of 31 December 2013, death or out-migration. Adult life expectancy was computed as the area under the Kaplan-Meier survival curve for each calendar year. It can be interpreted as the number of additional years that an adult-- here defined as 15 years old-- can expect to live under the age- and sex- specific mortality rates that prevail in a particular year.

For all-cause and cause-specific mortality analyses, individuals contributed exposure time during their residence in the DSS from the start of July 2005 (when ART was first available in the district and population-representative HIV test data were available in the DSS), or their date of in-migration if later, until the earliest of 30 June 2014, death or out-migration. Returning and repeat migrants only contributed person-years while resident in the DSS area. HIV status and ART treatment status were treated as time-varying covariates. Person-years were classified as HIV-negative up to 3 years after the latest HIV-negative test unless there was an earlier positive test. Person-years were classified as HIV-positive after a positive test. All other periods (before the first HIV test and \> 3 years after the latest negative test) were classified as HIV status unknown, to avoid selection bias.

For individuals who reported ART initiation at a clinic outside the district before July 2005, only person-years from study entry at 1 July 2005 contributed to this analysis. ART uptake in HIV-positive individuals was classified according to ever use and duration of treatment. Individuals were categorized as 'ever started on ART' from the first ART start date and as 'not (yet) on ART' for the period between an HIV-positive test result and an ART start date, if one existed, or to study exit. In those who ever started ART, individuals were also categorized by duration of antiretroviral treatment, with early treatment defined as less than 6 months on ART (as this has been shown to be a high-risk period[@dyw208-B19]^,^[@dyw208-B20]^)^ and longer-term treatment defined as 6 months or longer.

Age- and sex-specific mortality rates were calculated for three periods of ART availability/scaling-up; early (July 2005 to June 2008), mid (July 2008 to June 2011) and late (July 2011 to June 2014), and using age categories 15--24, 25--34, 35--44, 45--54, 55--64 and 65 years or more. To account for changing age structure in the population, age-standardized mortality rates were calculated by using the total population during the follow-up period as the standard population.

All-cause and cause-specific (HIV-related, non-HIV-related) mortality rate ratios were calculated by period of ART availability using Poisson regression. To examine the role of factors that might affect the association between period of ART availability and risk for all-cause and cause-specific mortality, participants were grouped according to sex, HIV infection and ART uptake, location of residence, age group and highest attained level of education, with adjustment for these factors where appropriate. Likelihood ratio χ[@dyw208-B2] tests were used to test for difference in the risk for all-cause and cause-specific deaths in adults over the three calendar periods. Tests for heterogeneity were calculated by entering a term for the interaction between the time period and the co-factor variable in the logistic regression models, and the statistical significance of the interaction terms were calculated with likelihood ratio tests.

These demographic data represent an open cohort, with mortality outcomes available for all those remaining resident in the DSS area. To understand better the extent to which different population sub-groups (who may be at higher risk for death) are associated with risk for departure from the DSS, we conducted an exploratory analysis. All calculations used Stata version 14.0 (Stata Corporation, College Station, TX).

Ethics approval for the studies was granted by the National Health Sciences Research Committee of Malawi (NHSR \#419, \#424, \#448, \#968 and \#1072) and the Ethics Committee of the London School of Hygiene & Tropical Medicine (\#5081, \#5067, \#5214, \#6126 and \#6303).

Results
=======

After excluding 11 individuals with indeterminate HIV test results or a single negative test after an earlier positive result, and 26 individuals with an ART start date but a later HIV-negative test result, 14 845 men and 17 819 women aged 15 years and older contributed a total of 161 849 person years and 1424 deaths between July 2005 and June 2014. Of 1930 individuals identified as HIV-positive during follow-up, ART uptake was established for 1382 individuals: 1192 (86%) via a clinic register link and 190 (14%) via self-report. Data on WHO stage at ART initiation were available for 97% of those with a clinic register link: initiation at WHO stage four declined from 33% in July 2005--June 2008, to 8% in July 2008--June 2011 and then to 7% in July 2011--June 2014 (data not shown in table).

All-cause adult age-standardized mortality rates declined from 11.3/1000 person-years (py) in July 2005--June 2008, to 10.7/1000 py in July 2008--June 2011 and then to 7.5/1000 py in July 2011--June 2014. Overall life expectancy at age 15 increased from 42.5 (95% CI 37.5--48.4) to 57.9 years (95% CI 53.8--62.1) in men between 2003 and 2010 and from 45.5 (95% CI 39.6--51.5) to 61.8 (95% CI 58.0--66.9) in women between 2003 and 2011, and then plateaued: attaining life expectancy comparable to that observed in HIV-negative men and women ([Figure 1a](#dyw208-F1){ref-type="fig"} and [b](#dyw208-F1){ref-type="fig"}).

![Life expectancy at 15 years in women (a) and men (b): 2003-2013.](dyw208f1){#dyw208-F1}

Age-specific mortality rates and rate ratios in men and women in the three periods of ART availability by sex and 10-year age groups are shown in [Table 1](#dyw208-T1){ref-type="table"}. In men and women, mortality was lowest in those aged 15--24 years and highest in those aged 65 years and older, with no evidence for change over time. A large reduction in mortality was observed in women aged 25 to 44 years and men aged 25 to 54 years between the early and mid-period of ART availability. In the late period, these mortality reductions were sustained in women and men aged 25 to 44 years but not in men aged 45 to 54 years. Table 1.Age specific mortality rates for adults 15 years and older by sex and period of ART availabilityPerson- yearsDeathsRate/1000 py95% CICrude mortality rate ratio95% CIAdjusted mortality rate ratio[^a^](#tblfn2){ref-type="table-fn"}95% CI*P*-value[^b^](#tblfn3){ref-type="table-fn"}Male, age, years 15--24  Jul 05--Jun 088940141.60.9--2.61.01.0  Jul 08--Jun 118910141.60.9--2.71.00.5--2.11.10.5--2.2  Jul 11--Jun 149968181.81.1--2.91.20.6--2.31.20.6--2.30.9 25--34  Jul 05--Jun 086220467.45.5--9.91.01.0  Jul 08--Jun 116316243.82.5--5.70.50.3--0.80.50.3--0.9  Jul 11--Jun 146534253.82.6--5.70.50.3--0.80.50.3--0.90.01 35--44  Jul 05--Jun 0835215816.512.7--21.31.01  Jul 08--Jun 113968338.35.9--11.70.50.3--0.80.50.3--0.8  Jul 11--Jun 1445204710.47.8--13.80.60.4--0.90.60.4--0.90.004 45--54  Jul 05--Jun 0820064120.415.1--27.81.01.0  Jul 08--Jun 112311198.25.2--12.90.40.2--0.70.40.2--0.7  Jul 11--Jun 1426303513.39.6--18.50.70.4--1.00.70.4--1.10.004 55--64  Jul 05--Jun 0813193224.317.2--34.31.01.0  Jul 08--Jun 1113472720.013.7--29.20.80.5--1.40.90.5--1.4  Jul 11--Jun 1414751912.98.2--20.20.50.3--0.90.60.3--1.00.1 65+  Jul 05--Jun 0816987544.235.2--55.41.01.0  Jul 08--Jun 1117399454.044.1--66.11.20.9--1.71.31.0--1.8  Jul 11--Jun 1418557540.432.2--50.70.90.7--1.31.00.7--1.40.2Female, age, years  15--24  Jul 05--Jun 089356131.40.8--2.41.01.0  Jul 08--Jun 119477151.61.0--2.61.10.5--2.41.30.6--2.8  Jul 11--Jun 1410698181.71.1--2.71.20.6--2.51.40.7--2.90.6 25--34  Jul 05--Jun 086894649.37.3--11.91.01  Jul 08--Jun 117298233.22.1--4.70.30.2--0.50.30.2--0.6  Jul 11--Jun 147802212.71.8--4.10.30.2--0.50.30.2--0.5\< 0.001 35--44  Jul 05--Jun 0839334210.77.9--14.51.01.0  Jul 08--Jun 114359245.53.7--8.20.50.3--0.90.50.3--0.9  Jul 11--Jun 145156193.72.4--5.80.30.2--0.60.40.2--0.60.001 45--54  Jul 05--Jun 0826403011.47.9--16.31.01.0  Jul 08--Jun 112860227.75.1--11.70.70.4--1.20.70.4--1.2  Jul 11--Jun 143149247.65.1--11.40.70.4--1.10.70.4--1.20.3 55--64  Jul 05--Jun 0817913419.013.6--26.61.01.0  Jul 08--Jun 1119292010.46.7--16.10.50.3--0.90.60.3--1.0  Jul 11--Jun 1420432210.87.1--16.40.60.3--1.00.60.3--1.00.1 65+  Jul 05--Jun 08225411852.443.7--62.71.01.0  Jul 08--Jun 11234210243.535.9--52.90.80.6--1.10.80.6--1.1  Jul 11--Jun 14259111745.237.7--54.10.90.7--1.10.90.7--1.10.4[^1][^2][^3]

All-cause crude mortality rates and rate ratios adjusted for sex, age group, location of residence and education are shown in [Table 2](#dyw208-T2){ref-type="table"}. After adjusting for other factors there was a 30% reduction in mortality in the adult population between the early and mid-period of ART availability, which was sustained during the late period. Mortality rates were similar in men and women in the early period but a greater reduction was observed in women (30%) than men (20%), although there was no evidence for heterogeneity in the association by sex (*P*-heterogeneity = 0.4). The fall was sustained in both sexes in the late period (July 2011 to June 2014). Table 2.All-cause mortality for adults aged 15 years and older by period of ART availability and HIV infection/ART usePerson-yearsDeathsRate/1000 py95% CICrude mortality rate ratio95% CIAdjusted mortality rate ratio[^a^](#tblfn4){ref-type="table-fn"}95% CIAdjusted mortality rate ratio[^b^](#tblfn5){ref-type="table-fn"}95% CI*P*-value[^c^](#tblfn6){ref-type="table-fn"} Overall population Period of ART  Jul 05--Jun 085057156711.210.3--12.21.01.01.0  Jul 08--Jun 11528574177.97.2--8.70.70.6--0.80.70.6--0.80.70.6--0.8  Jul 11--Jun 14584214407.56.9--8.30.70.6--0.80.70.6--0.80.70.6--0.8\< 0.001Sex by period of ART Male  Jul 05--Jun 082370326611.210.0--12.71.01.01.0  Jul 08--Jun 112459152118.67.5--9.80.80.6--0.90.80.6--0.90.80.7--0.9  Jul 11--Jun 142698122198.17.1--9.30.70.6--0.90.70.6--0.90.80.6--0.90.004 Female  Jul 05--Jun 082686830111.210.0--12.51.01.01.0  Jul 08--Jun 11282662067.36.4--8.40.70.5--0.80.60.5--0.80.70.6--0.8  Jul 11--Jun 14314392217.06.2--8.00.60.5--0.70.60.5--0.70.70.5--0.8\< 0.001HIV infection/ART use by period of ART HIV-negative  Jul 05--Jun 084876173.52.2--5.61.01.01.0  Jul 08--Jun 11350801734.94.2--5.71.40.9--2.31.10.7--1.81.10.7--1.8  Jul 11--Jun 14327001625.04.2--5.81.40.9--2.31.10.7--1.81.10.7--1.90.9 HIV-positive; ever on ART  Jul 05--Jun 085313769.750.5--96.11.01.01.0  Jul 08--Jun 1117716335.627.8--45.50.50.3--0.80.50.3--0.70.50.3--0.7  Jul 11--Jun 1427106022.117.2--28.50.30.2--0.50.30.2--0.50.30.2--0.5\< 0.001 HIV-positive; not (yet) on ART  Jul 05--Jun 083902051.333.1--79.51.01.01.0  Jul 08--Jun 1114841812.17.6--19.30.20.1--0.40.20.1--0.40.20.1--0.4  Jul 11--Jun 1410641716.010.0--25.70.30.2--0.60.30.1--0.50.30.1--0.5\< 0.001 HIV status unknown  Jul 05--Jun 084474249311.010.1--12.01.01.01.0  Jul 08--Jun 111452316311.29.6--13.11.00.9--1.20.90.8--1.11.00.8--1.1  Jul 11--Jun 14219472019.28.0--10.50.80.7--1.00.80.7--1.00.90.7,--1.00.2HIV-positive ever on ART[^d^](#tblfn7){ref-type="table-fn"} HIV-positive; \< 6 months on treatment  Jul 05--Jun 0816024149.4100.2--222.91.01.01.0  Jul 08--Jun 1123825105.271.8--155.70.70.4--1.20.70.4--1.20.70.4--1.2  Jul 11--Jun 14154852.026.0--103.90.30.2--0.80.30.2--0.80.30.1--0.70.01 HIV-positive; ≥ 6 months on treatment  Jul 05--Jun 083711335.120.4--60.41.01.01.0  Jul 08--Jun 1115333824.818.0--34.10.70.4--1.30.70.3--1.20.70.3--1.2  Jul 11--Jun 1425865220.315.5--26.70.60.3--1.10.50.3--1.00.50.3--1.00.20HIV-positive; not (yet) on ART Male  Jul 05--Jun 08146748.122.9--100.91.01.01.0  Jul 08--Jun 115711017.59.4--32.60.40.1--1.00.40.1--0.90.400.1--1.0  Jul 11--Jun 14458919.610.2--37.80.40.2--1.10.40.1--1.00.400.1--1.00.13 Female  Jul 05--Jun 082441353.330.9--91.71.01.01.0  Jul 08--Jun 1191388.84.4--17.50.20.1--0.40.10.1--0.40.20.1--0.4  Jul 11--Jun 14606813.26.6--26.40.20.1--0.60.20.1--0.50.20.1--0.6\< 0.001HIV-positive; not (yet) on ART Location of residence \< 1 km from tarmac  Jul 05--Jun 082161569.541.9--115.21.01.01.0  Jul 08--Jun 1177967.73.5--17.10.10.04--0.30.10.04--0.30.10.04--0.3  Jul 11--Jun 14593813.56.7--27.00.20.1--0.50.20.1--0.40.20.1--0.4\< 0.001 Location of residence \> 1 km from tarmac  Jul 05--Jun 08171528.812.0--69.11.01.01.0  Jul 08--Jun 116741217.09.7--30.00.60.2--1.70.50.2--1.50.50.2--1.6  Jul 11--Jun 14456919.19.9--36.70.70.2--2.00.50.2--1.60.60.2--1.70.50[^4][^5][^6][^7][^8]

Large reductions in mortality were observed in HIV-positive individuals on ART, with crude mortality (CMR) falling from 69.7/1000 py in July 2005--June 2008 to 35.6/1000 py in July 2008--June 2011 to 22.1/1000 py in July 2011--June 2014. A large fall in mortality was observed in HIV-positive individuals not (yet) on ART between the early and middle period (CMR 51.3 vs 12.1/1000 py; aRR 0.2; 95% CI: 0.1--0.4) that was sustained in the late period. Among those who started ART, mortality in the early stages of ART treatment (\< 6 months) declined over time from 149.4/1000 py in the early period, to 105.2/1000 py in the middle period and then to 52.0/1000 py in the late period (*P* = 0.01). There was no evidence for a decline in mortality in those on longer-term treatment (\> 6months) (*P* = 0.2), or in HIV-negative (*P* = 0.9) or HIV-unknown individuals (*P* = 0.2) over the study period, although mortality remained lowest in HIV-negative individuals.

In HIV-positive individuals not (yet) on ART, mortality was higher in women than men in the early period of ART availability and greater mortality reductions were observed in women than in men (53.3 to 13.2 per 1000 py in women vs 48.1 to 19.6 per 1000 py in men), although there was no evidence that the association differed by sex (*P*-heterogeneity = 0.5). Mortality was higher among HIV-positive individuals not on ART and living close to a tarmac road during the early period of ART availability compared with those living further away; however, those close to the tarmac road experienced a greater decline in mortality between the early and late period than those living further away (69.5 to 13.5/1000 py vs 28.8 to 19.1/1000 py ([Table 2](#dyw208-T2){ref-type="table"}). Figure 2a-c shows declining mortality in men and women in the total adult population ([Figure 2a](#dyw208-F2){ref-type="fig"}) and in HIV-positive individuals ([Figure 2b](#dyw208-F2){ref-type="fig"}), including men and women not (yet) on ART ([Figure 2c](#dyw208-F2){ref-type="fig"}).

![Adult mortality rate ratios of the association between period of ART availability and (a) sex; (b) HIV infection and ART use, and; (c) sex in those not (yet) on ART.](dyw208f2){#dyw208-F2}

[Table 3](#dyw208-T3){ref-type="table"} shows that HIV-related mortality in adults declined by 70% between the early and late period of ART availability (CMR 3.4 vs 1.2/1000 py; aRR 0.3; 95% CI: 0. 2--0.4), evident in both men and women (*P* \< 0.001). Mortality due to HIV-related causes declined progressively in HIV-positive individuals on treatment, with a 70% lower rate of HIV-related deaths in the late ART period compared with the early period (58.4 vs 17.0 per 1000 py; *P* \< 0.001). Large declines in HIV-related deaths were also observed in HIV-positive individuals not (yet) on ART (70%). In those who ever started ART, early mortality (\< 6 months on treatment) due to HIV-related causes dropped from 130.8/1000 py to 54.3/1000 py and then to 45.5/1000 py over the three time periods (*P* = 0.02). Table 3.HIV-related mortality for adults 15 years and older by period of ART availability and HIV infection/ART usePerson- yearsHIV- related deathsRate/1000 py95% CICrude mortality rate ratio95% CIAdjusted mortality rate ratio^a^95% CIAdjusted mortality rate ratio[^b^](#tblfn9){ref-type="table-fn"}95% CI*P*-value[^c^](#tblfn10){ref-type="table-fn"}Overall population Period of ART  Jul 05--Jun 08505711743.43.0--4.01.01.01.0  Jul 08--Jun 1152857731.41.1--1.70.40.3--0 .50.40.3--0.50.40.3--0.5  Jul 11--Jun 1458421691.20.9--1.50.30.3--0.50.30.2--0.40.30.2--0.4\< 0.001Sex Male  Jul 05--Jun 0823703913.83.1--4.71.01.01.0  Jul 08--Jun 1124592371.51.1--2.10.40.3--0.60.40.3--0.50.40.3--0.5  Jul 11--Jun 1426981351.30.9--1.80.30.2--0.50.30.2--0.50.30.2--0.5\< 0.001 Female  Jul 05--Jun 0826868833.12.5--3.81.01.01.0  Jul 08--Jun 1128266361.30.9--1.80.40.3--0.60.40.3--0.60.40.3--0.6  Jul 11--Dec1331439341.10.8--1.50.40.2--0.50.30.2--0.50.30.2--0.5\< 0.001HIV infection/ART use by period of ART HIV-positive; ever on ART  Jul 05--Jun 085313158.441.0--83.01.01.01.0  Jul 08--Jun 1117715138.821.9--37.90.50.3--0.80.50.3--0.70.50.3--0.7  Jul 11--Jun 1427104617.012.7--22.70.30.2--0.50.30.2--0.40.30.2--0.4\< 0.001 HIV-positive; not (yet) on ART  Jul 05--Jun 083901230.817.5--54.21.01.01.0  Jul 08--Jun 11148596.13.2--11.70.20.1-- 0.50.20.1--0.50.20.1--0.5  Jul 11--Jun 1410641110.35.7--18.70.30.1-- 0.80.30.1--0.70.30.1--0.70.001 HIV status unknown  Jul 05--Jun 08447421312.92.5--3.51.01.01.0  Jul 08--Jun 1114523120.80.5--1.50.30.2--0.50.30.2--0.50.30.1--0.5  Jul 11--Jun 1421947120.50.3--1.00.20.1--0.30.20.1--0.40.20.1--0.3\< 0.001HIV-positive ever on ART[^d^](#tblfn11){ref-type="table-fn"} HIV test positive; \< 6 months on treatment  Jul 05--Jun 0816121130.885.3--200.51.01.01.0  Jul 08--Jun 112382054.354.3--130.50.60.3--1.20.60.3--1.10.60.3--1.2  Jul 11--Jun 14154745.520.7--95.40.30.1--0.80.30.1--0.80.30.1--0.70.02 HIV test positive; ≥ 6 months on treatment  Jul 05--Jun 083711027.014.5--50.21.01.01.0  Jul 08--Jun 1115333120.214.2--28.70.70.4--1.50.70.4--1.50.700.4--1.5  Jul 11--Jun 1425563915.311.1--20.90.60.3--1.10.50.3--1.10.500.3--1.10.2[^9][^10][^11][^12][^13]

In this adult population there was no evidence for a decline in non-HIV-related mortality between the early and late time periods of ART availability ([Table 4](#dyw208-T4){ref-type="table"}; 6.7 vs 5.6/1000 py; aRR 0.9; 95% CI 0. 8--1.0; *P* = 0.2), and with no evidence for difference between men and women (*P*-heterogeneity = 0.4). Between the early and late periods, a large drop in non-HIV-related mortality was observed in HIV-positive individuals not (yet) on treatment (18.0 vs 3.8 per 1000 py; aRR 0.2; 95% CI 0.1--0.6; *P* = 0.02) that was not seen in HIV-positive individuals on ART, HIV-negative or HIV-unknown individuals. Table 4.Non-HIV-related mortality for adults 15 years and older by period of ART availability and HIV infection/ART usePerson-yearsNon-HIV-related deathsRate/1000 py95% CICrude mortality rate ratio95% CIAdjusted mortality rate ratio^a^95% CIAdjusted mortality rate ratio[^b^](#tblfn16){ref-type="table-fn"}95% CI*P*-value[^c^](#tblfn14){ref-type="table-fn"}Overall population Period of ART  Jul 05--Jun 08505713416.76.1--7.51.01.01.0  Jul 08--Jun 11528573135.95.3--6.6‐0.90.8--1.00.90.8--1.00.90.8--1.1  Jul 11--Jun 14584213255.65.0--6.2‐0.80.7--1.00.80.7--1.00.90.8--1.00.2Sex Male  Jul 05--Jun 08237031546.55.5--7.6‐1.01.01.0  Jul 08--Jun 11245921586.45.5--7.5‐1.00.8--1.21.00.8--1.21.030.8--1.3  Jul 11--Jun 14269811636.05.2--7.0‐0.90.7--1.20.90.7--1.21.000.8--1.21.00 Female  Jul 05--Jun 08268681877.06.0--8.0‐1.01.01.0  Jul 08--Jun 11282661555.54.7--6.4‐0.80.6--1.00.80.6--1.00.80.7--1.0  Jul 11--Jun 14314391625.24.4--6.0‐0.70.6--0.90.70.6--0.90.80.6--1.00.04HIV infection/ART use by period of ART HIV-negative4876153.11.9--5.1‐1.01.01.0  Jul 05--Jun 08350801574.53.8--5.2‐1.50.9--2.51.10.7--1.91.10.7--1.9  Jul 08--Jun 11327001494.63.9--5.41.50.9--2.51.20.7--2.01.20.7--2.00.8  Jul 11--Jun 14 HIV-positive; ever on ART  Jul 05--Jun 08531611.35.1--25.11.01.01.0  Jul 08--Jun 111771116.23.4--11.20.50.2--1.50.50.2--1.30.50.2--1.3  Jul 11--Jun 142710124.42.5--7.80.40.1--1.00.40.1--1.00.30.1--0.90.1 HIV-positive; not (yet) on ART  Jul 05--Jun 08390718.08.6--37.7‐1.01.01.0  Jul 08--Jun 11148496.13.2--11.70.30.1--0.90.30.1--0.80.30.1--0.8  Jul 11--Jun 14106443.81.4--10.00.20.1--0.70.20.1-- 0.60.20.1--0.60.02 HIV status unknown  Jul 05--Jun 08447743137.06.3--7.8‐1.01.01.0  Jul 08--Jun 11145231369.47.9--11.11.31.1--1.61.21.0--1.51.21.0--1.5  Jul 11--Jun 14219471607.36.2--8.5‐1.00.9--1.31.00.8--1.21.10.9--1.30.10HIV-positive ever on ART^d^ HIV test positive; \< 6 months on treatment  Jul 05--Jun 08161318.76.0--54.5‐1.01.01.0  Jul 08--Jun 11238416.86.4--45.30.90.2--4.00.90.2--3.90.90.2--4.1  Jul 11--Jun 1415416.51.0--50.4‐0.30.04--3.30.30.04--3.30.30.04--3.30.6 HIV test positive; ≥ 6 months on treatment  Jul 05--Jun 0837138.12.6--25.11.01.01.0  Jul 08--Jun 11153374.62.2--9.60.60.1--2.20.40.1--1.70.40.1--1.7  Jul 11--Jun 142556114.32.4--7.80.50.1--1.90.40.1--1.60.40.1--1.50.5[^14][^15][^16][^17][^18]

Out-migration from the study population was associated with unknown HIV status (aRR HIV unknown vs HIV-negative 2.0; 95% CI 1.9--2.1); with being younger (aRR 15--24 vs 65 years or older 8.1; 95% CI 7.2--9.2); with female sex (aRR female vs male 1.2; 95% CI 1.2--1.3), and; with higher educational attainment (aRR secondary vs none/incomplete primary 4.2; 95% CI 3.6--4.8; results not shown in a table), after controlling for potential confounders.

Discussion
==========

Our data show that total population adult life expectancy at age 15 in rural northern Malawi increased by almost 10 years between 2005 and 2011 and then plateaued, reaching the life expectancy estimate of HIV-negative individuals. Our results are of a similar or greater magnitude to the increases in mean length of life observed elsewhere in high HIV prevalence sub Saharan Africa where national ART programmes exist.[@dyw208-B7]^,^[@dyw208-B21] In our population, the observed increase in adult life expectancy is largely a result of the decline in adult mortality of HIV-positive individuals during a 9-year period of ART scale-up, decentralized care and annual household-level HIV testing, with almost universal acceptance of test results.[@dyw208-B16]^,^[@dyw208-B22]

The large reductions in all-cause and HIV-related mortality over time in those not (yet) on ART indicates a shift in ART initiation, from late-stage AIDS to an earlier phase of infection, getting HIV-positive individuals onto treatment early, leaving only relatively healthy positive individuals without (or yet to start) treatment. The sustained reduction in mortality over time in HIV-positive individuals and reduction in HIV-related mortality are consistent with our earlier findings[@dyw208-B13] and confirm that the early success of the ART programme[@dyw208-B12] has continued over the longer term in this rural, resource-constrained setting. However, our results suggest that smaller gains are being made in men than in women, particularly among those who are HIV-positive and yet to start ART. These findings indicate that men with a positive HIV diagnosis are remaining, to a greater extent than women, without treatment until too late into the disease: a finding consistent with other studies from sub-Saharan Africa.[@dyw208-B23] In our setting, the late treatment occurred even though the individuals were aware of their HIV status, an issue that may be important to consider as the global impetus for achieving 90‐90‐90 targets intensifies, requiring initiation of ART immediately after testing HIV positive.[@dyw208-B10]^,^[@dyw208-B11]

Among HIV-positive individuals, the initially high mortality in the first 6 months of treatment more than halved over time as individuals moved onto treatment at an earlier stage of disease (evidenced by 7% initiating ART in WHO stage 4 in the late phase, compared with 33% in the early phase); but it remained a high-risk period, as observed elsewhere.[@dyw208-B24] The large decline in HIV-related deaths in those of unknown HIV status suggests that few undiagnosed HIV-positive individuals remain in the surveillance population, following high participation rates in multiple HIV sero-surveys, during which 95% received their results.[@dyw208-B16] Access difficulties, including distance to clinics and transport costs, are established barriers for linkage to and retention in care.[@dyw208-B25] In Malawi, decentralization of ART services is associated with improved retention of patients in care.[@dyw208-B17] However, lower declines in all-cause and HIV-related mortality were observed in those living in more rural areas compared with those living close to a tarmac road, which may suggest more unmet need peripherally despite decentralization.

Our study linked annual sero-survey HIV test results and ART clinic data from across the surveillance population, which facilitated categorization of individuals according to HIV status and ART uptake to investigate in detail the impact of ART on mortality over time. However, our data include a relatively small HIV-positive adult population, so the confidence intervals on our mortality estimates are wide, particularly for age-group categories and other sub-group analyses. Nonetheless, HIV testing was provided in the community to a population representative sample between 2005 and 2006 and across all adults (15 years and older) between 2007 and 2011, so selection bias should not be a major concern for our study. HIV-unknown individuals contributed the largest proportion of person-years in the early phase of ART availability but, since HIV testing across the entire population did not start until 2007, the unknown population is likely to be representative of the overall population. Inclusion of undiagnosed, late-stage HIV-positive individuals in the HIV-unknown group will have contributed to the higher HIV-related mortality in the early period compared with the late period, when fewer chronically undiagnosed HIV-positive individuals remain in the population. Adults of unknown HIV status, young individuals, women and those with higher educational attainment were most at risk of out-migration from the DSS. Data on the health status of out-migrants at the time of departure (or their subsequent survival or death) were not available, so the extent to which their departure affected our mortality and life expectancy estimates could not be determined. However, in other settings where tracking of out-migrants has been implemented, higher mortality in those individuals has been reported,^(^[@dyw208-B26]^)^ so it is possible that our results (and those from other DSS and open cohort studies) somewhat underestimate mortality and overestimate life expectancy gains. It is also possible that compared with the general population, higher life expectancy gains were observed in our surveillance population where health-related research has been conducted for many years. We have previously shown that during this time period, an increasing proportion of verbal autopsy informants reported that they knew the deceased's HIV status, and the HIV status recorded on the verbal autopsy report influences the way the clinician reviewer assigns cause of death irrespective of symptoms.[@dyw208-B27] Hence it is possible that our findings underestimate to some extent the true gains in HIV-related mortality although, given the stable estimates of non-HIV-related mortality, misclassification is unlikely to be a major issue.

As the numbers of infected individuals surviving on ART increase; long-term retention and adherence; onward transmission from those who have interrupted treatment; and, identification of virological failure in long-term ART users, will be a challenge for the current public health programme and require ongoing monitoring and evaluation. In 2011, Malawi expanded the criteria for ART eligibility to include HIV-positive individuals with CD4 counts \< 350 cell/mm^3^, and initiation of life-long treatment in pregnant and breastfeeding women irrespective of disease severity,[@dyw208-B28] and to HIV-positive individuals with CD4 counts \< 500/mm[@dyw208-B3] from July 2014 onwards.[@dyw208-B29] These changes facilitate earlier initiation and increase the numbers of individuals alive on ART, but the sustained gains in adult life expectancy depend on continued access to effective treatment and high levels of retention and adherence of those in care. With a growing number of individuals surviving on ART, early identification of virological failure with the option to switch treatment at decentralized clinics is needed but will be a challenge in this setting

Conclusions
-----------

Our results suggest that large reductions in adult mortality and increasing adult life expectancy have been achieved in rural -Malawi over a 9-year period of ART availability, as HIV infected individuals move into care at an earlier stage of disease. HIV-positive men may be more likely than women to remain without ART until a late stage of disease. These data confirm that the success achieved in the early phase of ART availability has continued, highlighting the success of the public health approach to HIV care in Malawi. Improvement in mortality was observed in those who have accessed care and also in those not yet in care.
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Key Messages
------------

A sustained increased adult life expectancy during a period of decentralized ART care in Malawi.A decline in all-cause and HIV-related mortality in HIV-positive adults on and not (yet) on ART.Suggests earlier uptake of ART in women than in men.Success of a public health approach to ART provision in Malawi.

[^1]: py, person-years; June, June; Jul, July; -, range.

[^2]: ^a^Adjustment made for location of residence (\< 1 km, ≥ 1 km from roadside), education (none/incomplete primary, complete primary, incomplete secondary, complete secondary/tertiary, unknown), where appropriate.

[^3]: ^b^*P*-value test for difference in the association between time-period of ART availability (July 2005--June 2008, July 2008--June 2011 and July 2011--June 2014) and mortality, calculated with a likelihood ratio test.

[^4]: Jun, June; Jul, July; py, person-years; -, range.

[^5]: ^a^Adjustment made for age (15--24, 25--34, 35--44, 45--54, 55--64, 65+ years), sex (male, female), where appropriate.

[^6]: ^b^Adjustment made for age (15--24, 25--34, 35--44, 45--54, 55--64, 65+ years), sex (male, female), location of residence (\< 1 km, ≥ 1 km from roadside), education (none/incomplete primary, complete primary, incomplete secondary, complete secondary/tertiary, unknown), where appropriate.

[^7]: ^c^*P*-value test for difference in the association between period of ART availability (July 2005--June 2008, July 2008--June 2011 and July 2011--June 2014) and mortality, calculated with a likelihood ratio test.

[^8]: ^d^In those who used ART during follow-up, the data are presented by duration of treatment (\< 6 and ≥ 6 months).

[^9]: Jun, June; Jul, July; py, person-years; -, range.

[^10]: ^a^Adjustment made for age (15--24, 25--34, 35--44, 45--54, 55--64, 65+ years), sex (male, female), where appropriate.

[^11]: ^b^Adjustment made for age (15--24, 25--34, 35--44, 45--54, 55--64, 65+ years), sex (male, female), location of residence (\< 1 km, ≥ 1 km from roadside), education (none/incomplete primary, complete primary, incomplete secondary, complete secondary/tertiary, unknown), where appropriate.

[^12]: ^c^*P*-value test for difference in the association between period of ART availability (July 2005--June 2008, July 2008--June 2011 and July 2011--June 2014) and mortality, calculated with a likelihood ratio test.

[^13]: ^d^In those who used ART during follow-up, the data are presented by duration of treatment (\< 6 and ≥ 6 months).

[^14]: Jun, June; Jul, July; py, person-years; -, range.

[^15]: ^a^Adjustment made for age (15--24, 25--34, 35--44, 45--54, 55--64, 65+ years), sex (male, female), where appropriate.

[^16]: ^b^Adjustment made for age (15--24, 25--34, 35--44, 45--54, 55--64, 65+ years), sex (male, female), location of residence (\< 1 km, ≥ 1 km from roadside), education (none/incomplete primary, complete primary, incomplete secondary, complete secondary/tertiary, unknown), where appropriate.

[^17]: ^c^*P*-value test for difference in the association between period of ART availability (July 2005--June 2008, July 2008--June 2011 and July 2011--June 2014) and mortality, calculated with a likelihood ratio test.

[^18]: ^c^In those who used ART during follow-up, the data are presented by duration of treatment (\< 6 and ≥ 6 months).
